August 1, 2008
Dr. George Poste Named Non-Executive Vice Chairman of CDX Holdings, Parent of Caris Diagnostics and Caris Molecular Diagnostics
IRVING, Texas, Aug. 1 /PRNewswire/ -- CDX Holdings, a newly-formed holding company that is the parent company of Caris Diagnostics (Caris Dx) and Caris Molecular Diagnostics (CMDx), announced today that George Poste, D.V.M., Ph.D, F.R.C. Path, F.R.S., will be expanding his involvement with the company, serving as Non-Executive Vice Chairman and Chief Scientific Advisor of CDX Holdings and Non-Executive Chairman of CMDx. Dr. Poste has been a Director of Caris Dx, and now CDX Holdings, since November of 2006. He also acts as Senior Technical Advisor to Caris, Ltd., which owns a controlling stake in CDX Holdings.
Dr. Poste is Chief Scientist of the Complex Adaptive Systems Initiative and Director of The Biodesign Institute at Arizona State University. The research programs led by Dr. Poste combine research in biotechnology, nanotechnology, materials science and advanced computing. He also serves as Chief Executive of Health Technology Networks, a consulting firm that specializes in the application of genomic technologies and computing in healthcare. From 1992 to 1999, he was Chief Science and Technology Officer and president of Research & Development for SmithKline Beecham, where he oversaw the registration of 31 drug, vaccine and diagnostic products. Dr. Poste is a Fellow of the Royal College of Pathologists, a Fellow of the Royal Society and the UK Academy of Medicine, a Distinguished Fellow at the Hoover Institution of Stanford University and a member of the Council for Foreign Relations.
"George has been an invaluable asset to Caris since he first joined our Board in 2006. We look forward to getting the benefit of the additional contributions that George now will be able to offer in his more active role within our companies," said David D. Halbert, Chairman of CDX Holdings. "His understanding and foresight in diagnostics and personalized medicine is tremendous. He was instrumental in formulating our strategy that brought us into molecular diagnostics with our acquisition of Molecular Profiling, Inc., now called Caris MPI and the key subsidiary of CMDx, at the beginning of the year."
Dr. Poste has published over 350 scientific papers and co-edited 14 books on cancer, drug delivery and health policy. In 2004 he was named "R&D Scientist of the Year" by R&D Magazine and in 2006 he received the Einstein award from the Global Business Leadership Council. He previously served as chairman of the task force on bioterrorism for the U.S. Department of Defense. He serves as a member of the Defense Science Board of the Department of Defense and the Institute of Medicine Board of Global Health.
"I am honored to have the opportunity to work more closely with the distinguished team David has assembled at Caris Dx and Caris MPI," commented Dr. Poste. "I have appreciated the interactions I have experienced with the group in the past two years in forging the union of anatomic pathology and molecular diagnostics. I look forward to influencing and driving the companies' mission to accelerate the delivery of the highest quality personalized medicine into the marketplace to improve patient care and the efficient use of healthcare resources."
About CDX Holdings
CDX Holdings is the parent company of Caris Diagnostics and Caris Molecular Diagnostics, whose principal subsidiary is Caris MPI. Through its subsidiaries, CDX Holdings is a leading provider of the highest quality diagnostic, translational development and pharmaceutical services encompassing anatomic pathology and molecular testing. Formed in 1996, the company is headquartered in Irving, Texas, operates four laboratories: Irving, Texas; Phoenix, Arizona (2 sites); and Newton, Massachusetts, and provides services to well over 2,000 physicians nationally.
Caris Diagnostics provides world-class pathology services to physicians who treat patients in the community setting. The company provides academic-caliber medical consults through its industry-leading team of subspecialty fellowship and expert-trained pathologists in gastrointestinal and liver pathology, dermatopathology and hematopathology. Caris Diagnostics provides the highest levels of service to its customers and their patients through its state-of-the-art laboratories; proprietary, advanced clinical and technology solutions; and rigorous quality assurance programs.
Caris MPI provides advanced molecular analyses of patient samples through prognostic testing services and genomic and proteomic profiling to provide critical information to physicians treating cancer and other complex diseases. Furthermore, Caris MPI supports pharmaceutical companies and other researchers in their clinical trials for targeted therapeutics with custom genomic and proteomic analyses, analyte preservation, tissue procurement, and comprehensive reporting services. The company has strategic relationships with the International Genomics Consortium, US Oncology, the Translational Genomics Research Institute, and the Biodesign Institute of Arizona State University.
About Caris, Ltd.
Caris, Ltd. is a privately held investment partnership, with approximately $350 million of assets under management. Caris makes long-term, strategic investments principally in the private marketplace. Targeted sectors for Caris include health care, energy and financial services. Caris brings a successful track record of building sustainable business enterprises and partnering with management teams.
Additional information is available at http://www.carisdx.com/ and http://www.carismpi.com/ and http://www.carisltd.com/.
CONTACT: Leslie Brille, +1-212-521-4444
Web site: http://www.carisdx.com/http://www.carismpi.com/http://www.carisltd.com/